Gerresheimer GXI.DE XETRA · Healthcare · Germany
31.96 € +2.37% +0.74 €
Summary
37 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 16 EUR is left as free cash.
- The price moves less than the market (beta 0.47).
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 8.6 years of operating profit.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 8.5% a year. For the next fiscal year analysts expect revenue to grow by 0.9%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of 400.6M €.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 6.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail